Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | BRS3 | P32247 | 5/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | LATS1 | O95835 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142826 | 0.74 | GHSR (0.39) | NAMPTBRS3MAPTGSK3BRAB9A | |
| SCHEMBL27143602 | 0.69 | KDM4C (0.41) | KDM4CHIF1AKDM4E | |
| SCHEMBL5833311 | 0.69 | TSHR (0.49) | MAPTGSK3BKDM4CRAB9ASMN1; SMN2 | |
| SCHEMBL28293245 | 0.68 | ALDH1A1 (0.31) | SMN1; SMN2 | |
| SCHEMBL3194739 | 0.67 | MAPT (0.47) | MAPTKDM4CRAB9APOLBHPGD | |
| SCHEMBL28034764 | 0.65 | ACHE (0.32) | — | |
| SCHEMBL146430 | 0.64 | GHSR (0.41) | NAMPTBRS3RAB9A | |
| SCHEMBL30759275 | 0.64 | NAMPT (0.43) | NAMPTBRS3RAB9ALATS1 | |
| SCHEMBL28046351 | 0.64 | ALDH1A1 (0.30) | — | |
| SCHEMBL22075773 | 0.64 | LATS1 (0.44) | NAMPTBRS3RAB9ALATS1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545051-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-04-19 | — | — | EP | disclosed |
| US-8354410-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | NAMPT 1820/4885BRS3 3567/4885MAPT 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.